By Professor Richard Bryan Lock

Journal articles

Kolb A; Gorlick R; Houghton P; Morton C; Lock RB; Tajbakhsh M; Maris JM; Reynolds CP; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing of dasatinib by the Pediatric Preclinical Testing Program.', Pediatric Blood and Cancer, 50, pp. 1198 - 1206

Maris JM; Courtright J; Houghton P; Morton C; Gorlick R; Kolb EA; Lock RB; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA, 2008, 'Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.', Pediatric Blood and Cancer, 50, pp. 581 - 587

Dilda P; Perrone G; Philp A; Lock RB; Dawes IW; Hogg PJ, 2008, 'Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid', International Journal of Biochemistry and Cell Biology, 40, pp. 1016 - 1029, http://dx.doi.org/10.1016/j.biocel.2007.11.002

Lock RB; Neale G; Su X; Morton CL; Phelps D; Gorlick R; Reynolds CP; Maris JM; Friedman HSEA, 2008, 'Molecular characterization of the pediatric preclinical testing panel', Clin Cancer Res, 14, pp. 4572 - 4583

Brands K; Colvin EK; Williams LJ; Wang R; Lock RB; Tuch BE, 2008, 'Reduced immunogenicity of first-trimester human fetal pancreas.', Diabetes, 57, pp. 627 - 634, http://dx.doi.org/10.2337/db07-0720a

Choo A; Palladinetti P; Holmes TA; Basu S; Shen S; Lock RB; O Brien T; Symonds GP; Dolnikov A, 2008, 'siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.', International Journal of Oncology, 33, pp. 175 - 183

Smith MA; Morton CL; Phelps DA; Kolb EA; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ, 2008, 'Stage 1 Testing and Pharmacodynamic Evaluation of the HSP90 Inhibitor Alvespimycin (17-DMAG, KOS-1022) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 51, pp. 34 - 41

Markovic A; Mackenzie KL; Lock RB, 2007, 'Induction of vascular endothelial growth factor secretion in acute leukemia cells via the FLT-3 signaling pathway', MOLECULAR CANCER THERAPEUTICS, 6, pp. 3344S - 3344S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Courtright J; Friedman H; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds P; Morton CL; Smith MA, 2007, 'Initial testing of the histone deacetylase inhibitor Vorinostat by the Pediatric Preclinical Testing Program', MOLECULAR CANCER THERAPEUTICS, 6, pp. 3600S - 3601S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000805&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Courtright J; Friedman HS; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton CL; Smith MA, 2007, 'Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib', MOLECULAR CANCER THERAPEUTICS, 6, pp. 3471S - 3471S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000417&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Friedman HS; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshlava N; Reynolds CP; Morton CL; Smith MA, 2007, 'Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454', MOLECULAR CANCER THERAPEUTICS, 6, pp. 3405S - 3405S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MA; Maris JM; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2007, 'Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG', Journal of Clinical Oncology, 25, pp. 3575 - 3575, http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3575

Kang MH; Kang Y; Szymanska B; Wilczynska-Kalak U; Sheard M; Harned TM; Lock RB; Reynolds CP, 2007, 'Activity of vincristine, L-ASP and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo', Blood, 110, pp. 2057 - 2066

Whiteford CC; Bilke S; Greer B; Chen Q; Braunschweig TA; Cenacchi N; Wei JS; Smith MA; Houghton PJ; Morton CL; Reynolds CP; Lock RB; Gorlick R; Khanna C; Thiele CJ; Takikita M; Catchpoole DR; Hewitt SM; Khan J, 2007, 'Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis', Cancer research, 67, pp. 32 - 40

Bachmann PS; Gorman R; Papa R; Marshall GM; Lock RB, 2007, 'Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia', Cancer research, 67, pp. 4482 - 4490

Bachmann PS; Lock RB, 2007, 'In vivo models of childhood leukemia for preclinical drug testing', Current Drug Targets, 8, pp. 773 - 783

Xue C; Haber M; Flemming C; Marshall GM; Lock RB; Mackenzie K; Norris MD; Gurova K; Gudkov A, 2007, 'p53 determines multidrug sensitivity of childhood neuroblastoma.', Cancer research, 67, pp. 10351 - 10360

Morton CL; Papa RA; Lock RB; Houghton PJ, 2007, 'Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia and disseminated neuroblastoma', Curent Protocols in Pharmacology, pp. 14.8.1 - 18.4.20

Houghton P; Morton C; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb A; Zhang W; Lock RB; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA, 2007, 'The Paediatric Preclinical Testin Program: Description of models and early testing results.', Pediatric Blood and Cancer, 49, pp. 928 - 940

Lee E; Bachmann PS; Lock RB, 2007, 'Xenograft models for the preclinical evaluation of new therapies in acute leukemia', Leukemia and Lymphoma, 48, pp. 659 - 668

Shaw SE; Haylock DN; Johnston HM; Lock R; Nilsson SK, 2006, 'The Role of Hyaluronic Acid in Normal and Perturbed Hemopoietic Stem Cell Biology.', Blood, 108, pp. 708 - 708, http://dx.doi.org/10.1182/blood.v108.11.708.708

Houghton PJ; Maris JM; Friedman HS; Keir ST; Lock RB; Gorlick R; Kolb EA; Reynolds CP; Morton C; Smith MA, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor ispinesib (SB-715992)', EJC SUPPLEMENTS, 4, pp. 98 - 98, http://dx.doi.org/10.1016/S1359-6349(06)70318-4

Smith MA; Maris JM; Keir ST; Friedman HS; Lock RB; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825)', EJC SUPPLEMENTS, 4, pp. 101 - 101, http://dx.doi.org/10.1016/S1359-6349(06)70327-5

Smith MA; Maris JM; Keir ST; Lock RB; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the VEGFR-2 inhibitor AZD2171', EJC SUPPLEMENTS, 4, pp. 34 - 35, http://dx.doi.org/10.1016/S1359-6349(06)70108-2

Xu B; Wang BJ; Li AM; Lock R, 2006, 'Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia', Chinese Journal of Contemporary Pediatrics, 8, pp. 151 - 154

Mackenzie K; Lock RB, 2006, 'An endothelial metronome breast cancer?', Blood, 108, pp. 407 - 408

Verrills NM; Liaw TY; Lock RB; Kavallaris M; Liem N; Hood B, 2006, 'Proteomic anlaysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6, pp. 1681 - 1694

Hsu AK; Kerr BA; Jones KL; Lock RB; Hart DN; Rice AM, 2006, 'RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy', Biology of Blood and Marrow Transplantation, 12, pp. 855 - 867

Wen VW; Wu K; Baksh S; Hinselwood RA; Lock RB; Clark SJ; Moore MA; Mackenzie K, 2006, 'Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53 competent immortal endothelial cells', Cancer research, 66, pp. 10691 - 10700

Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock RB; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA, 2006, 'The Pediatric Preclinical Testing Program: description of models and early testing results', Pediatric Blood and Cancer

Choo A; Palladinetti P; Passioura TJ; Shen S; Symonds GP; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, 6, pp. 543 - 550

Choo A; Palladinetti P; Passioura T; Shen S; Lock R; Symonds G; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, 6, pp. 543 - 550

Bachmann PS; Gorman R; MacKenzie KL; Lutze-Mann L; Lock RB, 2005, 'Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor', Blood, 105, pp. 2519 - 2526

Markovic A; Mackenzie K; Lock RB, 2005, 'FLT-3: a new focus in the understanding of acute leukemia', International Journal of Biochemistry and Cell Biology, 37, pp. 1168 - 1172

Liem N; Papa R; Milross CG; Schmid M; Tajbakhsh M; Choi S; Ramirez C; Rice AM; Haber M; Norris MD; Lock RB, 2004, 'Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies', Blood, 103, pp. 3905 - 3914, http://dx.doi.org/10.1182/blood-2003-08-2911

Taylor LM; James A; Schuller C; Brce J; Lock RB; Mackenzie K, 2004, 'Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human M3C5 fibroblasts that overcome a telomere-independent crisis during immortalization', The Journal of Biological Chemistry, 279, pp. 43634 - 43635

Bendall LJ; Nilsson SK; Khan NI; Bonnet C; Lock RB; papa R; Bradstock KF; Gottlieb DJ, 2004, 'Role of CD44 variant exon 6 in acute lymphoblastic leukemia: Association with altered bone marrow localisation and inceased tumor burden.', Leukemia, 18, pp. 1308 - 1319

Lock RB, 2003, 'TCL1: A new drug target in lymphoid and ger-cell malignancies', International Journal of Biochemistry and Cell Biology, 35, pp. 1614 - 1618

Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA; Lock RB; Maris JM; Merlino G; Patterson W; Reynolds CP; Shannon K; Yu A; Yu J; Smith MA, 2002, 'Testing of new agents in childhood cancer preclinical models(meeting summary)', Clinical Cancer Research, 8, pp. 3646 - 3657

Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM, 2002, 'The non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of Childhood acute lymphblastic leukemia reveals intrinsic differences in biological characteristics at diagnosis and relapse', Blood, 99, pp. 4100 - 4108

Catts VS; Haber M; Norris MD; Lutze-Mann L; Lock RB, 2001, 'High Level resistance to Glucocorticoids, assosiated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, 15, pp. 929 - 935

Marshall GM; Norris MD; Lock RB; Peaston AE; Gardaneh M; Franco VA; Hocker JE; Murphy K; Farnsworth ML; Catchpoole DR; Haber M, 2001, 'MRP1 gene expression level regulates the death and differentation response of neuroblastoma cells', British Journal of Cancer, 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Catchpoole DR; Lock RB, 2001, 'The Potential Tumour Suppressor role for caspase-9 in the childhood malignancy, neoroblastoma', European Journal of Cancer, pp. 2217 - 2221

Murphy KD; Streips UN; Lock RB, 2000, 'Bcl-2 inhibits a Fas-induced conformational change in the Bas N terminus and Bax mitchondrial translocation', The Journal of Biological Chemistry, pp. 17225 - 17228

Murphy KD; Ranganathan V; Farnsworth ML; Kavallaris M; Lock RB, 2000, 'Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumour cells', Cell death and differentiation, pp. 102 - 111

Turnbull RM; Meczes EL; Rogers MP; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and β', Cancer Chemotherapy and Pharmacology, 44, pp. 275 - 282, http://dx.doi.org/10.1007/s002800050978

Murphy KD; Streips UN; Lock RB, 1999, 'Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2', Oncogene, 18, pp. 5991 - 5999

Elliott MJ; Murphy KD; Stribinskiene L; Ranganathan V; Sturges E; Farnsworth ML; Lock RB, 1999, 'Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide', Cancer Chemotherapy and Pharmacology, pp. 1 - 11

Turnbull RM; Meczes EL; Rogers M; Lock RB; Sullivan DR; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbanate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases II and B', Cancer Chemotherapy and Pharmacology, pp. 275 - 282

Elliot M; Stribinskiene L; Lock RB, 1998, 'Expression of Bcl-2 in human epithelial tumor (HeLA) cells enhances clonogenic survival following exposure to 5-fluoro-2-deoxyuridine or staurosporine, but not following exposure to etoposide or dosorubicin', Cancer Chemotherapy and Pharmacology, pp. 457 - 463

Back to profile page